On December 4, Gelonghui reported that Brightgene Bio-medical Technology Co., Ltd. (688166.SH) announced that its wholly-owned subsidiary, Brightgene Innovative Biomedical Technology (Wuxi) Co., Ltd. (referred to as "Brightgene Innovative"), has independently developed the BGM0504 injection's hypoglycemic indication Phase III clinical research plan, which has been approved by the ethics review committee of the lead hospital, Peking University People's Hospital, and received the "Ethics Review Approval Document from Peking University People's Hospital Ethics Review Committee."
The BGM0504 injection is a dual agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) independently developed by the company, classified as a Class 1 innovative drug that has not been launched domestically or internationally. The BGM0504 injection can activate the downstream pathways of GIP and GLP-1, producing biological effects such as controlling blood sugar, reducing weight, and treating non-alcoholic steatohepatitis (NASH), demonstrating potential for treating various metabolic diseases.
